Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity

Immunology

Volumn 137, Issue 3, 2012, Pages 226-238

  Weigand, Luise U ^a   Liang, Xiaoling ^a   Schmied, Sabine ^a   Mall, Sabine ^a   Klar, Richard ^b   Stötzer, Oliver J ^b   Salat, Christoph ^b   Götze, Katharina ^a   Mautner, Josef ^a   Peschel, Christian ^a   Krackhardt, Angela M ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Hämato Onkologische Schwerpunkt Praxis   (Germany)

^c Clinical Cooperation Group Antigen specific Immunotherapy   (Germany)

Author keywords

Leukaemia lymphoma myeloma; MHC HLA; T cell receptor (TCR); Therapy immunotherapy; Toll receptors Toll like receptors

Indexed keywords

FMNL1 LEUKEMIA ANTIGEN; HLA DR ANTIGEN; LEUKEMIA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE RELEASE; DENDRITIC CELL; EFFECTOR CELL; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; LEUKEMIA; LYMPHOMA CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TARGET CELL;

CELL LINEAGE; CELLS, CULTURED; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOID, ACUTE; LIGANDS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84866858992     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12000     Document Type: Article

References (42)

1. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112:4371-83.
2. Stanislawski T, Voss RH, Lotz C et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2:962-70.
3. Sadovnikova E, Stauss HJ. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci U S A 1996; 93:13114-8.
4. Schuster IG, Busch DH, Eppinger E et al. Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. Blood 2007; 110:2931-9.
5. Liang X, Weigand LU, Schuster IG et al. A single TCR α-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire. J Immunol 2010; 184:1617-29.
6. Li LP, Lampert JC, Chen X, Leitao C, Popovic J, Muller W, Blankenstein T. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med 2010; 16:1029-34.
7. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002; 100:2123-31.
8. Han Y, Eppinger E, Schuster IG, Weigand LU, Liang X, Kremmer E, Peschel C, Krackhardt AM. Formin-like 1 (FMNL1) is regulated by N-terminal myristoylation and induces polarized membrane blebbing. J Biol Chem 2009; 284:33409-17.
9. Parkhurst MR, Yang JC, Langan RC et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2010; 19:620-6.
10. Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W, Schendel DJ. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest 2010; 120:3869-77.
11. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4.
12. Katzman SD, Gallo E, Hoyer KK, Abbas AK. Differential requirements for Th1 and Th17 responses to a systemic self-antigen. J Immunol 2011; 186:4668-73.
13. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4.
14. + T cells. Cancer Res 2011; 71:2507-17.
15. + T cells against NY-ESO-1. N Engl J Med 2008; 358:2698-703.
16. + T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651-67.
17. + T lymphocytes. Cancer Res 2010; 70:8368-77.
18. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174:2591-601.
19. Porter DL. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Hematology Am Soc Hematol Educ Program 2011; 2011:292-8.
20. Ha SP, Klemen ND, Kinnebrew GH et al. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. J Clin Invest 2010; 120:4273-88.
21. Straetemans T, van Brakel M, van Steenbergen S et al. TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets. Clin Dev Immunol 2012; 2012:586314.
22. Leidi M, Gotti E, Bologna L et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009; 182:4415-22.
23. Moosmann A, Khan N, Cobbold M et al. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood 2002; 100:1755-64.
24. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, Mautner J. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 2003; 33:1250-9.
25. + T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol 2003; 171:219-25.
26. Kern F, Surel IP, Brock C et al. T-cell epitope mapping by flow cytometry. Nat Med 1998; 4:975-8.
27. Lefranc MP. IMGT databases, web resources and tools for immunoglobulin and T cell receptor sequence analysis, http://imgt.cines.fr. Leukemia 2003; 17:260-6.
28. Leisegang M, Engels B, Meyerhuber P et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med 2008; 86:573-83.
29. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006; 66:8878-86.
30. Voss RH, Kuball J, Engel R, Guillaume P, Romero P, Huber C, Theobald M. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol Res 2006; 34:67-87.
31. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67:3898-903.
32. Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, Meijer CJ, Schreurs MW, Hooijberg E. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006; 119:135-45.
33. Bendz H, Marincek BC, Momburg F, Ellwart JW, Issels RD, Nelson PJ, Noessner E. Calcium signaling in dendritic cells by human or mycobacterial Hsp70 is caused by contamination and is not required for Hsp70-mediated enhancement of cross-presentation. J Biol Chem 2008; 283:26477-83.
34. Kottke T, Errington F, Pulido J et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 2011; 17:854-9.
35. Morris GP, Ni PP, Allen PM. Alloreactivity is limited by the endogenous peptide repertoire. Proc Natl Acad Sci U S A 2011; 108:3695-700.
36. Cope A, Le Friec G, Cardone J, Kemper C. The Th1 life cycle: molecular control of IFN-γ to IL-10 switching. Trends Immunol 2011; 32:278-86.
37. Le Dieu R, Taussig DC, Ramsay AG et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009; 114:3909-16.
38. + T lymphocytes. Cancer Immunol Immunother 2008; 57:389-98.
39. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115:739-46.
40. + T cells in the circulation but not in the tumor site. J Immunol 2006; 177:1670-8.
41. Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours Oncogene 2008; 27:168-80.
42. Yu XZ, Martin PJ, Anasetti C. CD28 signal enhances apoptosis of CD8 T cells after strong TCR ligation. J Immunol 2003; 170:3002-6.